HEMATOLOGY / CLINICAL RESEARCH
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
More details
Hide details
1 |
Department of Medical Oncology, Health Sciences University, Gulhane Training
and Research Hospital, Ankara, Turkey |
2 |
Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana,
Turkey |
3 |
Department of Medical Oncology, Health Sciences University, Dr. Abdurrahman
Yurtaslan Training and Research Hospital, Ankara, Turkey |
4 |
Department of Medical Oncology, Medicalpark Hospital, Ankara, Turkey |
5 |
Department of Medical Oncology, Health Sciences University, Numune Training
and Research Hospital, Ankara, Turkey |
6 |
Department of Medical Oncology, Faculty of Medicine, Baskent University, Adana,
Turkey |
7 |
Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara,
Turkey |
8 |
Department of Haematology, Faculty of Medicine, Cukurova University, Adana,
Turkey |
9 |
Department of Haematology, Faculty of Medicine, Gazi University, Ankara, Turkey |
10 |
Department of Haematology, Faculty of Medicine, Koc University, Istanbul, Turkey |
11 |
Department of Haematology, Health Sciences University, Gulhane Training
and Research Hospital, Ankara, Turkey |
12 |
Department of Medical Oncology, Special Tinaztepe Hospital, Izmir, Turkey |
13 |
Department of Medical Oncology, Anatolian Health Center, Istanbul, Turkey |
Submission date: 2018-02-21
Final revision date: 2018-06-17
Acceptance date: 2018-08-07
Online publication date: 2019-02-18
Publication date: 2021-07-16
Arch Med Sci 2021;17(4):920–927
KEYWORDS
TOPICS
ABSTRACT
Introduction:
We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey.
Material and methods:
In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity.
Results:
Ninety-nine patients with a median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B-cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a median of three lines of chemotherapy (range: 2–8) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% ( = 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%).
Conclusions:
Objective response rate of bendamustine was found to be 74.3% in relapsed/refractory HL and NHL patients. It appears to be an effective option as a salvage treatment for patients who have previously received multiple lines of therapy.